PHAT Stock — Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. (PHAT)

Updated October 16, 2026.

PHAT is a Stock. Total return is -71.9% over the past 7 years, 251.6 points behind SPY at 179.7%.

Phathom Pharmaceuticals is a biopharmaceutical company developing treatments for gastrointestinal diseases, including VOQUEZNA and related combination therapies targeting erosive and non-erosive gastroesophageal reflux disease, Helicobacter pylori infection, and eosinophilic esophagitis. The company does not currently distribute dividends. Phathom appeals to investors seeking exposure to clinical-stage and early commercial-stage biotech companies rather than current income.

PHAT performance versus SPY

Price and return data through 2026-10-16.

Total return is -71.9% over the past 7 years, 251.6 points behind SPY at 179.7%. Over the past year its total return — price change plus distributions reinvested — is -48.0%. Its deepest 1-year drawdown was 62.9%.

PHAT key facts

Asset type

Stock

Asset class

Equity

Inception date

10/25/2019

Distribution frequency

None

Last close

$6.92 (as of 2026-10-16)

Market cap

$559,834,463

Average volume

1254200.0

Beta

0.502

Payout ratio

0.0%

Forward P/E

6.5963

EPS

$-1.26

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PHAT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 62.9%.

Who may consider PHAT — and who may not

It is a weaker fit for investors who need monthly cash flow (PHAT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PHAT

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions